Lung Cancer in the Era of Precision Medicine

Citation Report

#	ARTICLE	IF	CITATIONS
1	Nedaplatin: a new platinum for squamous lung cancer?. Lancet Oncology, The, 2015, 16, 1573-1574.	5.1	5
2	ATG7 promotes the tumorigenesis of lung cancer but might be dispensable for prognosis predication: a clinicopathologic study. OncoTargets and Therapy, 2016, Volume 9, 4975-4981.	1.0	15
3	HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncology Reports, 2016, 36, 589-597.	1.2	45
4	Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Molecular Cancer, 2016, 15, 67.	7.9	141
5	The path from big data to precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 129-143.	0.4	37
6	HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. Medical Oncology, 2016, 33, 50.	1.2	20
7	Mutational landscape of *EGFR-*, *MYC-*, and *Kras-* driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	3.3	158
8	Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control, 2016, 23, 338-346.	0.7	78
9	Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. EMBO Molecular Medicine, 2016, 8, 105-116.	3.3	18
10	Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncology, 2016, 5, 175-186.	1.2	11
11	Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends in Pharmacological Sciences, 2016, 37, 47-61.	4.0	190
12	Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discovery, 2016, 6, 14-16.	7.7	14
13	Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Molecular Oncology, 2016, 10, 330-343.	2.1	81
14	MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. Journal of Clinical Pathology, 2017, 70, 533-540.	1.0	24
15	Role of Imaging in the Era of Precision Medicine. Academic Radiology, 2017, 24, 639-649.	1.3	52
16	Personalized Pathway-Activated Systems Imaging in Oncology. , 2017, , .		1
17	SBI0206965, a novel inhibitor of Ulk1, suppresses non-small cell lung cancer cell growth by modulating both autophagy and apoptosis pathways. Oncology Reports, 2017, 37, 3449-3458.	1.2	81
18	Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib. Molecular Cancer Therapeutics, 2017, 16, 1634-1644.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine and Pharmacotherapy, 2017, 90, 24-37.	2.5	45
20	Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells. Cancer Science, 2017, 108, 2265-2272.	1.7	25
21	Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms. Molecular Cancer Therapeutics, 2017, 16, 2780-2791.	1.9	23
22	The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors. Neoplasia, 2017, 19, 695-706.	2.3	23
23	Metabolic Evaluation of Non‐Small Cell Lung Cancer Patient‐Derived Xenograft Models Using 18F-FDG PET: A Potential Tool for Early Therapy Response. Journal of Nuclear Medicine, 2017, 58, 42-47.	2.8	10
24	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2047-2063.	2.0	26
25	Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget, 2017, 8, 50209-50220.	0.8	145
26	The Lancet Psychiatry Commission on psychological treatments research in tomorrow's science. Lancet Psychiatry,the, 2018, 5, 237-286.	3.7	412
27	Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi Journal of Biological Sciences, 2018, 25, 888-894.	1.8	6
28	Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4031-S4033.	0.6	3
29	Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 6937-6945.	1.0	17
30	Association and clinical implication of the USP10 and MSH2 proteins in non‐small cell lung cancer. Oncology Letters, 2019, 17, 1128-1138.	0.8	11
31	Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. Cancer Management and Research, 2018, Volume 10, 4039-4050.	0.9	12
32	Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs. Future Medicinal Chemistry, 2019, 11, 1083-1086.	1.1	10
33	A laparoscopic resection of lung cancer metastatic to transverse colon: A case report and review of the literature. Clinical Case Reports (discontinued), 2019, 7, 1647-1650.	0.2	0
34	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
35	Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760.	0.8	14
36	Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 51-92.	0.1	1

#	Article	IF	Citations
37	Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-15.	0.5	28
39	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 888-899.	2.5	50
40	Tackling Lung Cancer Drug Resistance Using Integrated Drug-Repurposing Strategy. , 2019, , 549-575.		0
41	MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. Cancer Genomics and Proteomics, 2019, 16, 99-119.	1.0	48
42	PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma. Oncogenesis, 2019, 8, 22.	2.1	17
43	Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology, 2019, 96, 862-870.	1.0	10
44	Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. Cancer Journal (Sudbury, Mass), 2019, 25, 282-286.	1.0	9
45	Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management. Translational Lung Cancer Research, 2019, 8, S318-S320.	1.3	8
46	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
47	Systematic Identification of Multi Omics-based Biomarkers in <i>KEAP1</i> Mutated TCGA Lung Adenocarcinoma. Journal of Cancer, 2019, 10, 6813-6821.	1.2	7
48	A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer . Cancer Management and Research, 2019, Volume 11, 9469-9481.	0.9	1
49	microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance. International Journal of Molecular Sciences, 2019, 20, 6094.	1.8	20
50	Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Seminars in Cancer Biology, 2020, 61, 11-22.	4.3	11
51	Surgical Intervention and Its Clinical Significance of Gastrointestinal Metastasis from Lung Cancer: A Series of 14 Cases. Indian Journal of Surgery, 2020, 82, 540-544.	0.2	0
52	Personalizing medicine with pharmacogenetics and pharmacogenomics. , 2020, , 521-534.		2
53	circ2GO: A Database Linking Circular RNAs to Gene Function. Cancers, 2020, 12, 2975.	1.7	12
54	Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in nonâ€small cell lung cancer. Molecular Oncology, 2020, 14, 3135-3152.	2.1	30
55	Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutationâ€"Positive Lung Cancer Cells. Pharmaceutics, 2020, 12, 939.	2.0	15

#	Article	IF	Citations
56	Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093790.	1.4	39
57	Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway. Cancer Cell International, 2020, 20, 552.	1.8	49
58	Deep phenotyping of synovial molecular signatures by integrative systems analysis in rheumatoid arthritis. Rheumatology, 2021, 60, 3420-3431.	0.9	7
59	A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts. Cancer Research, 2020, 80, 4278-4287.	0.4	12
60	Artesunate inhibits epithelial-mesenchymal transition in non-small-cell lung cancer (NSCLC) cells by down-regulating the expression of <i>BTBD7</i>. Bioengineered, 2020, 11, 1197-1207.	1.4	11
61	Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer. European Journal of Medicinal Chemistry, 2020, 208, 112782.	2.6	15
62	World Lung Day: what, why, and where to?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L527-L533.	1.3	6
63	Denoising Autoencoder, A Deep Learning Algorithm, Aids the Identification of A Novel Molecular Signature of Lung Adenocarcinoma. Genomics, Proteomics and Bioinformatics, 2020, 18, 468-480.	3.0	18
64	Small Cell Lung Cancer: Advances in Diagnosis and Management. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 435-446.	0.8	10
65	Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e207205.	2.8	19
66	Identification key genes, key miRNAs and key transcription factors of lung adenocarcinoma. Journal of Thoracic Disease, 2020, 12, 1917-1933.	0.6	14
67	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	1.3	112
68	MiRNAs and LncRNAs: Dual Roles in TGF-Î² Signaling-Regulated Metastasis in Lung Cancer. International Journal of Molecular Sciences, 2020, 21, 1193.	1.8	51
69	Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer. Lung Cancer, 2020, 141, 97-100.	0.9	5
70	Antiproliferative and Antimetastatic Effects of Praeruptorin C on Human Non–Small Cell Lung Cancer through Inactivating ERK/CTSD Signalling Pathways. Molecules, 2020, 25, 1625.	1.7	14
71	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
72	MUC3A promotes non-small cell lung cancer progression via activating the NFÎºB pathway and attenuates radiosensitivity. International Journal of Biological Sciences, 2021, 17, 2523-2536.	2.6	8
73	DDIT4 overexpression associates with poor prognosis in lung adenocarcinoma. Journal of Cancer, 2021, 12, 6422-6428.	1.2	14

#	ARTICLE	IF	CITATIONS
74	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 139.	1.7	17
75	Precision Medicine in Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 433-466.	0.1	0
76	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response *In Vivo*. Cancer Discovery, 2021, 11, 1736-1753.	7.7	59
78	Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy. Current Medicinal Chemistry, 2021, 28, 963-985.	1.2	14
79	TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin. Molecular Pharmacology, 2021, 100, 144-154.	1.0	6
80	Absolute Neutrophil Count in the Peripheral Blood Predicts Prognosis in Lung Cancer Patients Treated with Anlotinib. Cancer Management and Research, 2021, Volume 13, 3619-3627.	0.9	4
81	SLC15A4 Serves as a Novel Prognostic Biomarker and Target for Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 666607.	1.1	3
82	Investigation of in vitro activities of Cu_2ZnSnS_4 nanoparticles in human non-small cell lung cancer. Materials Today Communications, 2021, 27, 102304.	0.9	3
83	Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes. , 0, , .		0
84	Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. JCO Oncology Practice, 2021, 17, e1012-e1020.	1.4	8
85	Hope and Worry. Cancer Nursing, 2021, Publish Ahead of Print, .	0.7	1
86	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. Cells, 2021, 10, 1988.	1.8	9
87	Artificial Intelligence in Cancer NOG/PDX Models—Prediction of Driver Gene Matching in Lung Cancer. Engineering, 2021, , .	3.2	2
88	Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals. Chest, 2021, 160, 1121-1130.	0.4	2
89	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers, 2021, 13, 4705.	1.7	86
90	Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters. Cancers, 2021, 13, 4413.	1.7	4
91	Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a037820.	2.9	9
92	Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis. Anti-Cancer Drugs, 2021, 32, 257-268.	0.7	8

#	Article	IF	Citations
95	Upregulation of the Coatomer Protein Complex Subunit beta 2 (COPB2) Gene Targets microRNA-335-3p in NCI-H1975 Lung Adenocarcinoma Cells to Promote Cell Proliferation and Migration. Medical Science Monitor, 2020, 26, e918382.	0.5	6
96	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget, 2016, 7, 84675-84687.	0.8	42
97	Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget, 2020, 11, 1399-1416.	0.8	16
98	Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. Oncotarget, 2016, 7, 24242-24251.	0.8	37
99	Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. , 2018, 1, 118-125.		13
100	Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells. Translational Cancer Research, 2020, 9, 5473-5483.	0.4	1
101	Exhaled Breath Condensate: A Non-Invasive Source for Tracking of Genetic and Epigenetic Alterations in Lung Diseases. Pharmaceutical Sciences, 2020, 27, 149-161.	0.1	6
102	Diagnostic Performance of Radial Probe Endobronchial Ultrasound without a Guide-Sheath and the Feasibility of Molecular Analysis. Tuberculosis and Respiratory Diseases, 2019, 82, 319.	0.7	18
103	Histone deacetylase 6-mediated downregulation of TMEM100 expedites the development and progression of non-small cell lung cancer. Human Cell, 2022, 35, 271-285.	1.2	10
104	Ethics, Regulations, and Clinical Development of Precision Medicine: Activating with Molecular Imaging. , 2017, , 105-126.		1
107	Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine. Respiratory Medicine, 2020, , 417-428.	0.1	0
108	SNX20 Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma. International Journal of General Medicine, 2021, Volume 14, 7599-7611.	0.8	5
109	My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. AMIA Summits on Translational Science Proceedings, 2016, 2016, 112-21.	0.4	11
110	Epigenetic Therapeutic Strategies to Target Molecular and Cellular Heterogeneity in Pancreatic Cancer. Visceral Medicine, 2022, 38, 11-19.	0.5	8
111	Lung cancer risk in never-smokers: An overview of environmental and genetic factors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 548-562.	0.7	13
112	First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer. Annals of Surgery, 2023, 277, e1143-e1149.	2.1	4
113	Evaluation of Predictors of the Effectiveness of Bronchoscopic Biopsies with Navigation by Endobronchial Ultrasound Mini Probes in Peripheral Lung Masses of Various Etiologies. Tuberculosis and Lung Diseases, 2022, 100, 24-32.	0.2	0
114	Inducible Co-Stimulator ICOS Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma. International Journal of General Medicine, 2022, Volume 15, 3739-3751.	0.8	4

#	Article	IF	Citations
115	Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity. Nuclear Medicine and Biology, 2022, 108-109, 70-75.	0.3	1
116	Comparison and Evaluation of Studies on Precision Medicine using AI. , 2022, , .		2
117	Prevalence of highly actionable mutations among Indian patients with advanced non‑small cell lung cancer: A systematic review and meta‑analysis. Asia-Pacific Journal of Clinical Oncology, 2023, 19, 158-171.	0.7	0
118	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Frontiers in Immunology, 2022, 13, .	2.2	7
119	Chemopreventive role of Tin oxide-Chitosan-Polyethylene glycol-Crocin nanocomposites against Lung cancer: An in vitro and in vivo approach. Process Biochemistry, 2022, 120, 186-194.	1.8	3
120	MicroRNA-877-5p Inhibits Cell Progression by Targeting FOXM1 in Lung Cancer. Canadian Respiratory Journal, 2022, 2022, 1-11.	0.8	1
121	EGFR, NF-κB and noncoding RNAs in precision medicine. Progress in Molecular Biology and Translational Science, 2022, , 189-218.	0.9	1
122	Comprehensive Genome Profiles Obtained by Next-generation Sequencing Using the Cytological Samples in Our Hospital. Japanese Journal of Lung Cancer, 2022, 62, 200-206.	0.0	2
123	The Therapy of Osimertinib for EGFR Mutation—Non-small Cell Lung Cancer. , 0, 6, 219-229.		0
124	m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression. Cell Death and Disease, 2022, 13, .	2.7	22
125	IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells. Science Signaling, 2022, 15, .	1.6	18
126	Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?. Cancers, 2022, 14, 3758.	1.7	3
127	Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. Npj Precision Oncology, 2022, 6, .	2.3	5
128	Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis. Health Data Science, 2022, 2022, .	1.1	0
129	Non-genetic stratification reveals epigenetic heterogeneity and identifies vulnerabilities of glycolysis addiction in lung adenocarcinoma subtype. Oncogenesis, 2022, 11, .	2.1	0
130	Impact of a Comprehensive Financial Resource on Financial Toxicity in a National, Multiethnic Sample of Adult, Adolescent/Young Adult, and Pediatric Patients With Cancer. JCO Oncology Practice, 2023, 19, e286-e297.	1.4	7
131	Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis. Genomics, Proteomics and Bioinformatics, 2022, 20, 850-866.	3.0	25
132	ANP32B promotes lung cancer progression by regulating VDAC1. Gene, 2023, 859, 147200.	1.0	0

#	Article	IF	Citations
133	Assessing patient-level knowledge of precision medicine in a community health center setting. Journal of Community Genetics, 2023, 14, 197-210.	0.5	1
134	Dexmedetomidine promotes necroptosis by upregulating PARP1 in non-small cell lung cancer. Biotechnology and Genetic Engineering Reviews, 0, , 1-21.	2.4	0
135	Precision Surgery in NSCLC. Cancers, 2023, 15, 1571.	1.7	5
136	Mechanism exploration and prognosis study of Astragali Radix-Spreading hedyotis herb for the treatment of lung adenocarcinoma based on bioinformatics approaches and molecular dynamics simulation. Frontiers in Chemistry, 0, 11, .	1.8	2
137	The Role of BTBD7 in Normal Development and Tumor Progression. Technology in Cancer Research and Treatment, 2023, 22, 153303382311677.	0.8	1
147	Epigenetic therapeutic strategies in pancreatic cancer. International Review of Cell and Molecular Biology, 2024, , 1-40.	1.6	0